Azithromycin Should NOT Be Used to Treat Brucellosis
Azithromycin is not recommended for the treatment of brucellosis due to unacceptably high failure and relapse rates, and it is not included in any guideline-recommended treatment regimens. The Ioannina Recommendations, which represent the international consensus on brucellosis treatment, do not list azithromycin as a treatment option at any level 1.
Evidence Against Azithromycin Use
Guideline Recommendations
The 2007 Ioannina Recommendations establish clear first-line and second-line regimens for uncomplicated brucellosis 1:
First-line regimens (AI recommendation):
- Doxycycline 100 mg twice daily for 6 weeks + Streptomycin 15 mg/kg daily IM for 2-3 weeks
- Doxycycline 100 mg twice daily for 6 weeks + Rifampicin 600-900 mg daily for 6 weeks
Acceptable alternative (BI recommendation):
- Doxycycline 100 mg twice daily for 6 weeks + Gentamicin 5 mg/kg daily parenterally for 7 days
Second-line regimens (CII recommendation):
- TMP-SMX-containing regimens
- Quinolone-containing combination regimens
Azithromycin is conspicuously absent from all recommended treatment tiers 1.
Clinical Trial Evidence Shows Poor Efficacy
The most compelling evidence against azithromycin comes from a clinical trial specifically evaluating its use in human brucellosis 2. In this study of 10 patients treated with azithromycin plus gentamicin:
- 50% of patients failed therapy (95% CI: 18.7%-81.3%)
- 3 patients relapsed after initial response
- The authors explicitly concluded: "these results do not favor the use of azithromycin to treat brucellosis in humans"
Animal Model Studies Confirm Inadequacy
Multiple animal studies demonstrate azithromycin's inferiority 3, 4:
- Azithromycin failed to cure experimental brucellosis in mice, while doxycycline-streptomycin achieved 100% cure rates 3
- Only 25-50% of mice treated with azithromycin survived lethal challenge, compared to 83-100% with doxycycline regimens 3, 4
- Even prolonged azithromycin therapy (21 days) could not match the effectiveness of standard doxycycline regimens 3, 4
Antimicrobial Susceptibility Data
Recent antimicrobial resistance surveillance reveals concerning patterns 5, 6:
- MIC90 values for azithromycin were 8 μg/mL, significantly higher than doxycycline (0.094 μg/mL) 5
- Macrolide resistance, particularly to azithromycin, is notably high in African Mediterranean countries 6
- A 2013 study explicitly concluded: "azithromycin has not been confirmed as an appropriate agent for the treatment" 5
Why Azithromycin Fails
Despite showing reasonable in vitro activity against Brucella (MIC90 0.5-1.0 μg/mL) 7, azithromycin fails clinically because:
- Inadequate intracellular penetration or activity where Brucella resides
- Insufficient bactericidal activity to prevent relapse
- Suboptimal pharmacokinetics for the prolonged treatment required in brucellosis
What You Should Use Instead
For uncomplicated brucellosis in adults, use:
- Doxycycline 100 mg PO twice daily for 6 weeks PLUS Streptomycin 1 g IM daily for 2-3 weeks (gold standard) 1
If streptomycin unavailable:
- Doxycycline 100 mg PO twice daily for 6 weeks PLUS Rifampicin 600-900 mg PO daily for 6 weeks 1
If aminoglycosides preferred but streptomycin unavailable:
- Doxycycline 100 mg PO twice daily for 6 weeks PLUS Gentamicin 5 mg/kg IV/IM daily for 7 days 1
Critical Pitfalls to Avoid
- Do not use azithromycin monotherapy or in combination regimens for brucellosis—the 50% failure rate is unacceptable 2
- Do not rely on in vitro susceptibility data alone—azithromycin demonstrates the disconnect between laboratory activity and clinical efficacy 7
- Do not use azithromycin as a substitute when standard regimens are contraindicated; instead, use guideline-recommended second-line options like TMP-SMX combinations 1
The FDA label for azithromycin does not list brucellosis as an approved indication 8, and the drug should only be used for proven or strongly suspected bacterial infections where it has demonstrated efficacy.